COMP <GO>
GGG vs TMO // EV/EBITDA & P/E VALUATION
Graco Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: GGG 10
— TMO 3
▲ EV/EBITDA & P/E VALUATION LEADER: GGG
LAST: $68.75 (+2.37%) • MKT CAP: $11.03B
valuation
15.7x
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GGG VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GGG | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 52.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 24.30% | 9.30% | +15.00 | GGG | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 15.7x | 30.4x | -14.70 | GGG | /valuation <GO> |
| Free Cash Flow Yield | 5.79% | 2.40% | +3.39 | GGG | /fcf-yield <GO> |
| Operating Margin | 27.90% | 17.40% | +10.50 | GGG | /operating-margins <GO> |
| Net Profit Margin | 23.30% | 15.10% | +8.20 | GGG | /net-margins <GO> |
| Revenue Growth (YoY) | 5.80% | 3.90% | +1.90 | GGG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.66% | 0.24% | +1.42 | GGG | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.51 | 4.50 | +2.01 | GGG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | GGG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.4 | 62.9 | -27.50 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.94 | -0.05 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.6x | 36.3x | -16.70 | GGG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.03B | $262.22B | -$251.19B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GGG REV | TMO REV | GGG GROSS % | TMO GROSS % | GGG FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.24B | $44.56B | 52.5% | — | $637.9M | $6.29B |
| FY 2024 | $2.11B | $42.88B | 53.1% | — | $515.0M | $7.27B |
| FY 2023 | $2.20B | $42.86B | — | — | $552.2M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GGG // BETA 0.89
TMO // BETA 0.94